Zydus Lifesciences gets NOC from Health Canada for ZDS-Varenicline tablets

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-08 04:30 GMT | Update On 2025-08-08 04:31 GMT

Ahmedabad: Zydus Lifesciences Limited has received NOC (Notice of Compliance) from Health Canada for ZDS-Varenicline tablets 0.5 &1 mg. This is the group’s first NOC approval in Canada.

Varenicline is used as an aid in smoking cessation. It is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain.

ZDS-Varenicline tablets will be produced at Zydus Lifescience Ltd, SEZ, Ahmedabad.

Varenicline tablets had annual sales of 15 mn Canadian dollar in Canada (IQVIA MAT December 2024).

This Canadian approval follows Zydus Lifesciences’ earlier approval in 2023, when it received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Varenicline Tablets, 0.5 mg and 1 mg (USRLD: Chantix Tablets).

Read also: USFDA approves Zydus Varenicline Tablets for smoking addiction treatment

Zydus Lifesciences Ltd. is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Zydus Lifesciences gets NOC from Health Canada for ZDS-Varenicline tablets

Similar News

CDSCO Tightens RTI Appeal Timelines, Division Heads to Face Penalties for Lapses

Patna HC Denies Bail in Codeine Syrup Case: Possession Below 2.5% Still NDPS Offence

Alembic Pharma Gets USFDA Nod for Generic Paxil CR Tablets

Game-Changer for HIV: Dr Reddy's, Hetero to Sell Generic Lenacapavir at Rs 3,547 a Year

Sanofi Commits USD 625 Million to Sanofi Ventures to Boost Biotech and Digital Health Startups

Syneos Health Asked to Clarify Phase II Tacrolimus Trial Protocol by CDSCO Panel

Zydus Lifesciences Gets CDSCO Panel Nod for Bioavailability Study of Antimalarial Candidate ZY-19489

Serum Institute, Vidal Health Partner for Digital Cashless HPV Vaccination Programme